These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1111 related articles for article (PubMed ID: 33632231)

  • 41. Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer.
    Ding D; Liang R; Li T; Lan T; Li Y; Huang S; He G; Ren J; Li W; Zheng Z; Chen T; Fang J; Huang L; Shuai X; Wei B
    J Control Release; 2024 May; 369():309-324. PubMed ID: 38554771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer.
    Sun Y; Liu L; Zhou L; Yu S; Lan Y; Liang Q; Liu J; Cao A; Liu Y
    ACS Appl Mater Interfaces; 2020 Oct; 12(41):45873-45890. PubMed ID: 32924511
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy.
    Li M; Zhao D; Yan J; Fu X; Li F; Liu G; Fan Y; Liang Y; Zhang X
    ACS Nano; 2024 May; 18(20):12870-12884. PubMed ID: 38727063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CXCR4-Targeted Macrophage-Derived Biomimetic Hybrid Vesicle Nanoplatform for Enhanced Cancer Therapy through Codelivery of Manganese and Doxorubicin.
    Jang Y; Cho YS; Kim A; Zhou X; Kim Y; Wan Z; Moon JJ; Park H
    ACS Appl Mater Interfaces; 2024 Apr; 16(14):17129-17144. PubMed ID: 38533538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
    Xu C; Liu W; Hu Y; Li W; Di W
    Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
    [TBL] [Abstract][Full Text] [Related]  

  • 46. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
    Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
    ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy.
    Du L; Gong Y; Zhang X; Sun J; Gao F; Shen M; Bai H; Yang T; Cheng X; Li S; Peng J; Liu Z; Ding S; Chen J; Cheng W
    J Nanobiotechnology; 2024 Jul; 22(1):442. PubMed ID: 39068444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer.
    Zhao P; Xu Y; Ji W; Zhou S; Li L; Qiu L; Qian Z; Wang X; Zhang H
    J Nanobiotechnology; 2021 Jun; 19(1):181. PubMed ID: 34120612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
    He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
    Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulating tumor innervation by nanodrugs potentiates cancer immunochemotherapy and relieve chemotherapy-induced neuropathic pain.
    Zuo S; Wang Z; Jiang X; Zhao Y; Wen P; Wang J; Li J; Tanaka M; Dan S; Zhang Y; Wang Z
    Biomaterials; 2024 Sep; 309():122603. PubMed ID: 38713972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes.
    Wu Y; Gu W; Li J; Chen C; Xu ZP
    Nanomedicine (Lond); 2019 Apr; 14(8):955-967. PubMed ID: 30901292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
    Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
    Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
    Li C; Han X
    Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
    Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
    Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.
    Bastaki S; Irandoust M; Ahmadi A; Hojjat-Farsangi M; Ambrose P; Hallaj S; Edalati M; Ghalamfarsa G; Azizi G; Yousefi M; Chalajour H; Jadidi-Niaragh F
    Life Sci; 2020 Apr; 247():117437. PubMed ID: 32070710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
    Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
    Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages.
    Zhang Y; Wu L; Li Z; Zhang W; Luo F; Chu Y; Chen G
    Biomacromolecules; 2018 Jun; 19(6):2098-2108. PubMed ID: 29634251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Biomimetic Nanogel System Restores Macrophage Phagocytosis for Magnetic Resonance Imaging-Guided Synergistic Chemoimmunotherapy of Breast Cancer.
    Li L; Gao Y; Zhang Y; Yang R; Ouyang Z; Guo R; Yu H; Shi X; Cao X
    Adv Healthc Mater; 2023 Oct; 12(26):e2300967. PubMed ID: 37470683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.